Bacteriocin-like inhibitory substance (BLIS) activity of Streptococcus macedonicus MBF10-2 and its synergistic action in combination with antibiotics
10.1016/j.apjtm.2017.11.001
- Author:
Sharon Edith GRAZIA
1
;
Sumayyah SUMAYYAH
1
;
Fakhri Subhana HAITI
1
;
Amarila MALIK
1
;
Muhamad SAHLAN
2
;
Muhamad SAHLAN
3
;
Nicholas C.K. HENG
4
Author Information
1. Pharmaceutical Microbiology and Biotechnology Research Group, Faculty of Pharmacy, Universitas Indonesia
2. Division of Bioprocess Engineering, Faculty of Engineering, Universitas Indonesia
3. Research Centre for Biomedical Engineering, Faculty of Engineering, Universitas Indonesia, UI Campus Depok
4. Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago
- Publication Type:Journal Article
- Keywords:
Bacteriocin-like inhibitory substance;
Deferred antagonism assay;
Lantibiotic;
Protein fractionation;
Streptococcus macedonicus;
Well diffusion assay
- From:
Asian Pacific Journal of Tropical Medicine
2017;10(12):1140-1145
- CountryChina
- Language:Chinese
-
Abstract:
Objective To characterize the bacteriocin-like inhibitory-substances (BLIS) activity of Streptococcus macedonicus MBF10-2 [named BLIS(MBF10-2)], a bacteriocinogenic strain isolated from an Indonesian tofu byproduct. Methods BLIS(MBF10-2) was obtained by culturing the bacterium, and standard deferred antagonism assays were used to demonstrate its activity. The antibacterial testing of fractions collected by filtration using 3–30 kDa cut-off membrane sizes were carried out by performing well diffusion method. Results The growth of Micrococcus luteus, Streptococcus pyogenes, Lactococcus lactis, Leuconostoc mesenteroides and Weissella confusa were inhibited by BLIS(MBF10-2). Interestingly, BLIS-containing fractions obtained from sequential application on ultrafiltration membranes indicated that this bacterium Streptococcus macedonicus MBF10-2 could produces at least two antimicrobial peptides activities, one of which is likely to be a lantibiotic peptide. Potential synergistic activity against certain Gram-positive (but not Gram-negative) species when partnered with antibiotics (ampicillin, tetracycline or kanamycin) were observed. Conclusion Combination of some BLIS(MBF10-2) active fractions with antibiotics (ampicillin, tetracycline or kanamycin) could demonstrate synergistic activities against certain Gram-positive species.
